Sun Pharmaceutical Industries Ltd has announced that it has entered into a definitive agreement under which it will acquire all outstanding shares of Organon for $14.00 per share in an all‑cash transaction with an enterprise valuation of $11.75 billion.

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021.